Market Research Study

According to MRFR analysis, the global  lymphedema diagnostics market  is expected to register a CAGR of ~7.1% during the forecast period and was valued at USD 22.6 million in 2018. Lymphatic obstruction or lymphedema is a long-term condition where the excess fluid forms in the body tissue and causes swelling commonly called edema. It develops due to the damaged lymphatic system. Sometimes it also develops after the treatment of breast cancer. The growth of the global lymphedema diagnostics market is determined by numerous factors such as increasing incidence of cancer, high prevalence of lymphedema, and the adoption of new diagnostic modalities. However, the short half-life of radiopharmaceuticals and the high cost of diagnostic tests is projected to restrain the growth of the market during the forecast period. The global lymphedema diagnostics market is currently dominated by several market players. The key players are involved in expansion, acquisition, and strategic collab...

According to MRFR analysis,  Somatostatin Analogs Market  is expected to register a CAGR of 6.8% during the forecast period and is anticipated to reach USD 8,640 Million by 2025. The growth of the global somatostatin analogs market is driven by various factors such as increasing research & development activity in the somatostatin analogs market and increasing numbers of players involved in the development of generic versions of somatostatin analogs. Some of the key companies operating in this market are Nodysis Pharma, United Biotech, Wockhardt, Neiss, Sun Pharma, and Ferring Holding SA, among others. In addition, the rising incidence rate of the NETs; and increasing efforts by government bodies and public and private organizations to increase awareness about Acromegaly are some of the other factors for the growth of the somatostatin analogs market. Somatostatin analogs drugs  stop the excessive hormone secretion in the body. Neuroendocrine Tumors (NETs) and Acromegal...

According to MRFR analysis,  Aortic Valve Market  is expected to register a CAGR of 11.1% during the forecast period and held a value of USD 6,454.91 Million in 2018. The growth of the global aortic valve market is boosted by various factors such as the rising geriatric population, surge in prevalence of cardiac disorders, in conjunction with the introduction of innovative products in the market. According to the Heart Valve Voice, approximately 1.5 million people over the age of 65 years are currently affected by heart valve disease in the UK, and the number is expected to increase up to 19 million by 2050. Moreover, increasing product approvals are likely to provide favorable conditions for the growth of the market. For instance, in June 2017, the US FDA granted market clearance for aortic and mitral valve-in-valve procedures using the Edwards Lifesciences Sapien 3 transcatheter heart valve (THV). An aortic valve is surgically implanted in the heart to replace a valve that h...

According to MRFR analysis,  ACE Inhibitors Market  is expected to register a CAGR of 3.10% during the forecast period and is likely to be valued at USD 7682.8 Million. The growth of the global ACE inhibitors market is determined by numerous factors such as rising adoption of ACE inhibitors for the treatment of cardiovascular complications and diabetic neuropathy, rising cases of cardiovascular disorders such as hypertension, and surge in demand for less expensive drugs. For instance, according to the data published by the World Health Organization (WHO) in 2017, the global prevalence rate of raised blood pressure in adults aged more than 18 was estimated to be 22.1% in 2017. However,  ace inhibitors side effects  associated with the treatment and high costs of treatment are likely to hamper the growth of the global ACE inhibitors market during the forecast period.  Regional Analysis The market has been divided, by region, into the Americas, Europe, Asia-Pacific...

According to MRFR analysis,  Life Science Analytics Market  is expected to register a CAGR of 11.91% during the forecast period and was valued at USD 19,165.22 Million in 2018. Life science analytics is a tool that helps in clinical trials standardization and optimization of the drug discovery process. The growth of the global life science analytics market can be contributed to growing pressure to curb the healthcare expenditure, need for improved data standardization, and increasing prevalence of chronic diseases. Furthermore, the growing adoption of analytics solutions in clinical trials, increasing adoption of analytics tools for sales & marketing applications, the need for improved patient outcomes, and rising adoption of big data in the life science industry are also expected to fuel the market growth during the forecast period. However, high implementation costs and lack of skilled professionals have expected to restrain the growth of the global life science analytic...

According to MRFR analysis,  Vertigo Treatment Market  is expected to register a CAGR of 4.2% during the forecast period and accounts for USD 1,800 million in 2018. Vertigo refers to a sense of spinning dizziness that can be caused by problems in the brain or inner ear, including sudden head movements, or inflammation in the inner ear due to a viral or bacterial infection. Vertigo can be treated with medications such as steroids that can reduce internal ear inflammation, and water pills that can reduce fluid buildup in the ear. The growth of the global vertigo treatment market is driven by various factors such as an increase in the prevalence of vertigo, increasing geriatric population, and rising government initiatives to create awareness of the market. However, lack of knowledge about the  vertigo symptoms  and causes of is projected to hamper the growth of the global vertigo treatment market. The global vertigo treatment market is currently dominated by several ma...

According to MRFR analysis , Hip Implants Market  is expected to register a CAGR of 4.1 %  during the forecast period and is expected to reach USD 9,300 Million by 2025. Hip replacement is a surgical procedure in which the hip joint is replaced by a prosthetic implant, which is also known as hip prosthesis.  Hip replacement surgery  can be performed as a hemi (half) replacement or total replacement. The growth of the global hip implants market is driven by various factors, such as the introduction of custom-made implants and the growing geriatric population. Increased product launches, mergers, acquisitions, and partnerships of the major players of the market attributed to the growth of the market. However, stringent government regulations on all-metal hip implants and an increase in the number of product recalls are projected to hamper the growth of the global hip implants market. Several market players currently dominate the ...

According to MRFR analysis,  Vitiligo Treatment Market  is expected to register a CAGR of 5.6% during the forecast period was valued at USD 1.22 Billion in 2018. Vitiligo is a skin disorder that causes white patches to appear on the skin. These patches occur because the melanocytes are destroyed, leaving areas of skin with no pigment at all. It can affect any skin part of the body. The growth of the global vitiligo treatment market is driven by various factors such as emerging therapies for skin disorders, increasing healthcare expenditure, lifestyle changes. However, the lack of skilled professionals is expected to curb the growth of the global vitiligo treatment market. Several market players currently dominate the global vitiligo treatment market. The key players are involved in product launches and strategic collaborations to strengthen their market positions. For instance, Incyte Corporation reported positive results from the study of ruxolitinib cream which is in phase 2...

According to MRFR analysis, the global  liver cirrhosis treatment market  is expected to register a CAGR of ~5.2% during the forecast period and was valued at USD 956.89 million in 2018. The growth of the global liver cirrhosis treatment market is driven by various factors such as an increasing global geriatric population, rising prevalence of liver cirrhosis, rapidly changing lifestyle, growing awareness programs regarding liver diseases, rising R&D investment for the development of innovative drugs for liver diseases, and increasing demand for better treatment methods for curing liver cirrhosis. However, stringent government regulations, high investment required for drug research & development, and side-effects of medications prescribed for liver cirrhosis are the factors that are expected to limit the growth of the global liver cirrhosis treatment market. Liver cirrhosis is basically the late-stage scarring of the liver caused due to various types of liver diseases ...

The Global   Onychomycosis Market   is expected to register a CAGR of 6.28% during the forecast period with a market value of USD 7,912.5 Million till 2025. Onychomycosis is a general term used to denote any fungal nail infection. Factors such as the surging diabetic patient population, rising per capita healthcare expenditure coupled with the rising occurrences of onychomycosis, are anticipated to fuel the growth of the global onychomycosis market. However, the lack of awareness about onychomycosis and the side-effects associated with onychomycosis treatment drugs is likely to hamper the market growth. Segment Analysis The global onychomycosis market, by type, has been divided into distal subungual onychomycosis (DSO),  white superficial onychomycosis (WSO) , proximal subungual onychomycosis (PSO), candida onychomycosis, and others. On the basis of treatment type, the global onychomycosis market has been divided into drug treatment, topical therapy, and others....

The Global   Cardiomyopathy Medication Market   is anticipated to reach USD 620 Million by 2025 at a CAGR of ~4.60% during the forecast period. Cardiomyopathy is a disease that causes the thickening and enlargement of the heart muscles and abnormal blood flow. Patients suffering from cardiomyopathy showcase symptoms such as dizziness, coughing, fatigue, and swelling of the legs, ankles, and feet. Certain factors that propel the growth of the global cardiomyopathy medication market are the high patient pool of heart disease, focus on manufacturing medication for cardiomyopathy treatment, and rising healthcare expenditure.  Currently, the global cardiomyopathy medication market is dominated by several players. The major players in this market are involved in strategic acquisitions and product launches to expand their product portfolios. For instance, in May 2019, Pfizer Inc. received US FDA approval for Vyndamax (tafamidis) and Vyndaqel (tafamidis meglumine) for the treatme...

According to MRFR analysis, the global  implantable cardioverter defibrillator (ICD) market  is expected to register a CAGR of 5.96% during the forecast period. Implantable Cardioverter Defibrillator (ICD) is used to record the heart's activity and treat dangerous ventricular arrhythmias with an electrical shock or pulse to the heart. Factors such as the growing aging population, changing lifestyles such as smoking and alcohol consumption, and the increase in demand for cardiac implants are responsible for the increasing prevalence of cardiac arrhythmias globally. This is likely to fuel the growth of the ICD market during the forecast period. In addition to this, improving efficacy of ICDs for the treatment of cardiac diseases over a period will also fuel the market. According to the American Heart Association, approximately 1.5 million cases of myocardial infarction occur annually, and the incidence rate is approximately 600 cases per 100,000 people in the US. According to th...